PK/PD analysis in assessment of abuse deterrence
|
|
- Mervyn Stafford
- 5 years ago
- Views:
Transcription
1 PK/PD analysis in assessment of abuse deterrence Megan J. Shram, PhD Director and Principal, Altreos Research Partners Inc. Adjunct Professor and Lecturer, Department of Pharmacology, University of Toronto INC Research Consultant ADF Science Meeting October 3 September 1, 213 Bethesda, MD
2 Acknowledgments Consultant to pharmaceutical and biotech companies Thank you to Purdue Pharma, LP for permission to present data on reformulated OxyContin and OXN
3 Outline Background on PK/PD in abuse potential What is PK/PD relationship of opioids? Determinants of variation Application of PK/PD analysis in development of abuse-deterrent formulations (ADF)
4 Introduction Draft Guidance on Assessment of Abuse Potential of Drugs (January 21): Characterization of the PK/PD properties of a product is important for determining the abuse potential of a product. Draft ADF guidance (January 213): PK data should be collected to correlate with the PD outcomes. The rate of rise of drug onset for the intact and manipulated potentially abuse-deterrent formulation should be given appropriate weight in the overall analysis of the abuse deterrent properties.
5 Introduction Goal of PK/PD analysis is to assist in predicting the effect of a drug over time, in relation to exposure In terms of abuse, the relationship between rate of rise of [drug] and effect is considered important Fast onset, short duration of action favors repeated self-administration Delaying onset, extending duration of action can reduce immediate reinforcing effect and need to take more drug
6 Questions Can PK assist in predicting subjective response to opioid? How can one assess if change in PK profile will be enough to affect PD response? eg, partial defeat of the AD mechanism
7 PK/PD: Determinants of Variation System Age Gender Opioid experience Tolerance/Dependence Expectations Genetic variations?? Endpoints Analysis Interpretation Pharmacokinetics (CV 3%) Opioid, Dose Formulation, Route BBB permeability ADME, protein binding Active metabolites Plasma vs. Effect site Arterial v venous sampling/timing CV=coefficient of variation Pharmacodynamics (CV 5- >1%) Subjective effects Miosis Analgesia Respiratory depression Adverse events Behavior
8 Assessing the link between opioid exposure and results of a clinical abuse potential study Recent ADF Examples
9 When PK/PD relationship might exist Physicochemical barrier Resistance to manipulation for oral, IN and IV* administration Prodrug Must be cleaved systemically to liberate active moiety Deterrence from IN and IV administration, and possibly oral if limited by saturable process Delivery System Modified drug delivery to reduce diversion via multiple routes *not generally feasible to administer manipulated product IV
10 PK/PD of intranasally administered Reformulated OxyContin 5-way crossover study in recreational opioid users with intranasal experience Coarse and fine ground OTR (3 mg) Positive controls: Oxy API and fine ground original OC (3 mg) Placebo control: lactose powder
11 Plasma oxycodone (ng/ml) Drug Liking VAS (-1) Time course of effects Oxycodone concentration Drug Liking VAS OTR fine OTR coarse OC OTR fine OTR coarse OC Time post-dose (hr) Time post-dose (hr) Effects unrelated to drug exposure can impact experience (at the moment and overall) Courtesy of Purdue Pharma; Perrino et al., 212 CPDD; Harris et al., submitted
12 Rate of Rise: Abuse quotient Lower C max and longer T max lower Abuse Quotient OTR fine OTR coarse OC OTR fine OTR coarse OC 14 Oxy API 14 Oxy API Cmax/Tmax Emax/TEmax Oxycodone Pharmacokinetics Drug Liking Visual Analog Scale Data courtesy of Purdue Pharma
13 Exposure-Response Relationship For reformulated OxyContin, delaying and lowering C max had significant impact on liking But if PK drives PD, what is concentrationeffect relationship?
14 Drug Liking VAS (-1) Drug Liking VAS (-1) PK/PD Correlations: Subjective Effects Derived Parameters By Timepoint OC fine Emax of Drug Liking VAS (-1) Overall R 2 =.12 Drug Liking VAS (-1) y =.2782x R² = Cmax of oxycodone (ng/ml) Plasma oxycodone concentration (ng/ml) OTR fine OTR coarse y =.5386x R² = y =.6612x R² = Plasma oxycodone concentration (ng/ml) Plasma oxycodone concentration (ng/ml) Data courtesy of Purdue Pharma
15 Pupil size (mm) Pupil size (mm) PK/PD Correlations: Physiological Effects y = -.249x R² =.2132 Pupil size (mm) MPC (mm) Derived Parameters By Timepoint 8 OC fine Overall R 2 = Cmax of oxycodone (ng/ml) Plasma oxycodone concentration (ng/ml) OTR fine OTR coarse y = -.59x R² = y = -.586x R² = Plasma oxycodone concentration (ng/ml) Plasma oxycodone concentration (ng/ml) Data courtesy of Purdue Pharma
16 When PK/PD might matter less Opioid agonist-antagonist combinations Antagonist attenuates/reverses effect of opioid Does PK of antagonist help predict response to agonist? Aversion Aversive agent not intended to impact exposure to agonist PK would NOT predict overall response to ADF Might still experience high from opioid; however, product not liked
17 PK/PD of intranasally administered OXN 3-way crossover study in recreational opioid users with intranasal experience Crushed OXN 4/2 mg (oxycodone/naloxone) Positive control: Oxy API 4 mg Placebo control: lactose powder
18 Plasma oxycodone (ng/ml) Time course of effects 1 Plasma Concentration 1 Drug Liking VAS Naloxone (ng/ml) Oxy API - Oxycodone OXN - Oxycodone Drug Liking VAS (-1) OXN Oxy API Placebo Time post-dose (hours) Time post-dose (hours) At 2:1 ratio, OXN significantly reduces Drug Liking to placebo-like levels Rate of rise: Abuse Quotient (C max /T max ) not applicable to opioid agonist-antagonist combinations, such as OXN Data courtesy of Purdue Pharma
19 Drug Liking VAS (-1) Antagonist PK Agonist PD y =.15x R² = Plasma naloxone concentration (ng/ml) Highly variable concentrations and lack of concentration-effect relationship of to-be-marketed formulation Relationship between antagonist PK and agonist PD typically evaluated earlier in development in dose-ranging trials ie, dose-effect Data courtesy of Purdue Pharma
20 Conclusions Relationship between PK and PD of abuse potential is weak and highly variable Effects unrelated to opioid exposure impact subject s experience Clinical PD study necessary to determine potential for abuse (or its deterrence) PK alone cannot be used as substitute in abuse potential assessment
Assessing the Clinical Abuse Potential of Abuse Deterrent Opioid Formulations
Assessing the Clinical Abuse Potential of Abuse Deterrent Opioid Formulations November 16, 2016 Beatrice Setnik, PhD VP, Clinical Pharmacology, Early Phase INC Research Disclosure I am an employee of INC
More informationReference ID: NDA was approved on December 12, The product was not formulated with properties to deter abuse,
tablets (NDA 020553). 1 According to Purdue, the reformulated OxyContin (OCR) had controlled-release features that would be less easily compromised by tampering than the original OxyContin (OC), and thereby
More informationDo Pre Marketing Studies Anticipate Post Market Consequences? A Case Study of Reformulated Oxycontin
Do Pre Marketing Studies Anticipate Post Market Consequences? A Case Study of Reformulated Oxycontin Edward M. Sellers MD, PhD, FRCPC, FACP Professor Emeritus, University of Toronto Principal, DL Global
More informationDocuments Regarding Drug Abuse Assessments
Overview of the FDA Guidance Documents Regarding Drug Abuse Assessments ABUSE DETERRENT FORMULATION SCIENCE MEETING DISCUSSION OF THE FDA DRAFT GUIDANCE FOR INDUSTRY: ABUSE DETERRENT OPIOIDS EVALUATION
More informationAbuse liability workshop. February 19, 2013
Abuse liability workshop February 19, 2013 Agenda Topic Presenter Duration Dinner 30 min Introduction Marta Sokolowska, PhD 5 min FDA Draft Guidance on Assessment of Abuse Potential of Drugs review of
More informationThe Evolution of Abuse Deterrent Drug Formulations: Testing Effectiveness from the Benchtop to the Real World
The Evolution of Abuse Deterrent Drug Formulations: Testing Effectiveness from the Benchtop to the Real World Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center Executive Director,
More informationIn Vitro Considerations for Development Abuse Deterrent Dosage Forms
In Vitro Considerations for Development Abuse Deterrent Dosage Forms Presentation to AAPS Annual Meeting Nov 3, 2014 Nagesh Bandi, Ph.D. Global CMC New Products Pfizer Inc. 1 Disclaimer The thoughts and
More information6/6/2017. The Role of ADFs in Curbing Opioid Abuse Can ADFs Reduce Opioid Abuse? 12-Month Financial Disclosures* Objectives
The Role of ADFs in Curbing Opioid Abuse Can ADFs Reduce Opioid Abuse? Lynn R. Webster, M.D. Vice President of Scientific Affairs PRA Health Sciences Salt Lake City, UT LRWebsterMD@gmail.com (801) 892-5140
More informationSetting the Stage: Are Abuse-Deterrent Opioids Formulations Ready for Prime Time?
Setting the Stage: Are Abuse-Deterrent Opioids Formulations Ready for Prime Time? Lewis S. Nelson, MD New York University School of Medicine New York City Poison Control Center Opioid Abuse Liability
More informationOpioid Analgesics with Abuse- Deterrent Properties: Current Data and Future Opportunities
1 National Academy of Medicine Session 4 Opioid Analgesics with Abuse- Deterrent Properties: Current Data and Future Opportunities Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center
More information25/03/2014. Workshop Overview. Hot Topics in FDA Regulations and Pharmacotherapy Research that Impact Patient Care:
Hot Topics in FDA Regulations and Pharmacotherapy Research that Impact Patient Care: Sharon L. Walsh, Ph.D. Shanna Babalonis, Ph.D. Michelle Lofwall, M.D. Center on Drug and Alcohol Research Department
More informationFDA Briefing Document
FDA Briefing Document Joint Meeting of Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee September 10 2015 Page 1 DISCLAIMER STATEMENT The
More informationA LOOK AT ABUSE-DETERRENT OPIOIDS
JULY 2017 Drugs Under Review ICER s report reviewed evidence on ten abuse-deterrent formulations (ADF) of opioids. Nine of the drugs were extended release (ER) opioids, and one was immediate release (IR).
More informationFDA Briefing Document
FDA Briefing Document Joint Meeting of Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee September 11, 2015 Page 1 DISCLAIMER STATEMENT The
More informationChallenges in Conducting Postmarketing Abuse Investigations
Challenges in Conducting Postmarketing Abuse Investigations Paul Coplan, ScD, MBA Risk Management & Epidemiology Purdue Pharma, L.P. ADF Guidance Meeting Washington DC, October 1, 2013 1 That which we
More informationAvailable for Public Release
FDA ADVISORY COMMITTEE BRIEFING DOCUMENT Xtampza ER (EXTENDED-RELEASE OXYCODONE) JOINT MEETING OF THE ANESTHETIC AND ANALGESIC DRUG PRODUCTS ADVISORY COMMITTEE AND THE DRUG SAFETY AND RISK MANAGEMENT ADVISORY
More informationOpioid Stewardship and Managing the Opioid Crisis: A Health-Care Perspective
Opioid Stewardship and Managing the Opioid Crisis: A Health-Care Perspective February 13, 2018 Frank Vocci, PhD New Therapies on the Horizon The planners, editors, faculty and reviewers of this activity
More informationCorporate Presentation (Nasdaq: COLL) June 1, 2015
Corporate Presentation (Nasdaq: COLL) June 1, 2015 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of
More informationT E C H N O L O G Y INTRODUCTION F I G U R E 1 F I G U R E 2
ABUSE DETERRENT T E C H N O L O G Y New Abuse Deterrent Formulation (ADF) Technology for Immediate-Release Opioids By: Johannes Bartholomäus, PhD; Sebastian Schwier, PhD; Martin Brett, Hans-Jürgen Stahlberg,
More informationEffect of Abuse-Deterrent Formulations and IR Opioids on Abuse, Overdose and Death from Rx Opioids
Effect of Abuse-Deterrent Formulations and IR Opioids on Abuse, Overdose and Death from Rx Opioids Richard C. Dart, MD, PhD Executive Director, RADARS System Professor, University of Colorado Competing
More informationA National Perspective on the Abuse and Diversion of Prescription Drugs
A National Perspective on the Abuse and Diversion of Prescription Drugs Hilary L. Surratt, Ph.D Steven P. Kurtz, Ph.D. ARSH: Center for Applied Research on Substance Use and Health Disparities Faculty
More informationCategory 4 Can we prove that ADF opioids really are?
Human Abuse Liability & Abuse-Deterrent Formulations Category 4 Can we prove that ADF opioids really are? March 7, 2016 Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center Executive
More informationDan Cohen Forum Chair - Abuse DeterrentCoalition. Abuse Deterrent Formulations of Opioids and the Abuse Deterrent Coalition
Dan Cohen Forum Chair - Abuse DeterrentCoalition Abuse Deterrent Formulations of Opioids and the Abuse Deterrent Coalition Prescription Drug Abuse and Diversion Partnering with Law Enforcement, Anti-Drug
More informationIdentifying Key Characteristics and Habits of the Recreational Drug User
Identifying Key Characteristics and Habits of the Recreational Drug User Beatrice Setnik, PhD VP Scientific & Medical Affairs, Early Phase CBI Abuse Deterrent Formulations Summit Alexandria, VA March 7,
More informationCurrent Challenges and Opportunities in Demonstrating Bioequivalence
Current Challenges and Opportunities in Demonstrating Bioequivalence Gur Jai Pal Singh, Ph.D. Watson Laboratories, Inc. Corona, California, USA Demonstrating Bioequivalence of Locally Acting Orally Inhaled
More informationClinical Trial Results Summary Study EN
Study Number: EN3288-113 Title of Study: A Double-blind, Dose-Ranging, Pilot Study to Evaluate the Safety, Subjective Effects, and Pharmacokinetics of Oxymorphone Hydrochloride in Healthy Subjects Who
More informationAbuse-Deterrent Formulations
Abuse-Deterrent Balancing Evidence with Value Tyson Thompson, PharmD Clinical Consultant Pharmacist University of Massachusetts Medical School Clinical Pharmacy Services Disclosure Statement I have no
More informationPURDUE PHARMA L.P. NDA Avridi (Immediate-Release Oxycodone Hydrochloride) Tablets
PURDUE PHARMA L.P. NDA 206830 Avridi (Immediate-Release Oxycodone Hydrochloride) Tablets Advisory Committee Briefing Materials For Joint Meeting of the Drug Safety and Risk Management Advisory Committee
More informationWhat is an opioid? What do opioids do? Why is there an opioid overdose crisis? What is fentanyl? What about illicit or bootleg fentanyls?
What is an opioid? What do opioids do? Why is there an opioid overdose crisis? What is fentanyl? What about illicit or bootleg fentanyls? What is an opioid? What do opioids do?: The term opioid can be
More informationDr. Nele Plock. Dr. N. Plock, March 11, 2008, American Conference on Pharmacometrics
Parallel PKPD modeling of an endogenous agonist (A) and exogenous antagonist (B) based on research PKPD data to predict an effective first-in-man dose of B A combination of physiologically based PK and
More informationWR Fentanyl Symposium. Opioids, Overdose, and Fentanyls
Opioids, Overdose, and Fentanyls Outline: What are opioids? Why are we experiencing and opioid crisis? Potency, purity, and product How do opioids cause overdose and overdose deaths? What is naloxone and
More informationA Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Analgesic Efficacy of MNK-795 Controlled-Release
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Analgesic Efficacy of MNK-795 Controlled-Release Oxycodone/Acetaminophen Tablets (CR OC/APAP) in an Acute Pain Model Neil
More informationAbuse of opioid painkillers in the US is a major problem
As appeared in January 2018 Tablets & Capsules www.tabletscapsules.com formulation Abuse-deterrent formulation technologies: Opportunities and limitations Alyn McNaughton Lonza Too many Americans are misusing
More informationFentanyls and Naloxone. Opioids, Overdose, and Naloxone
Opioids, Overdose, and Naloxone Presenter Disclosure Presenter s Name: Michael Beazely I have no current or past relationships with commercial entities Speaking Fees for current program: I have received
More informationDRAFT GUIDANCE DOCUMENT Comparative Bioavailability Standards: Formulations Used for Systemic Effects
1 2 3 DRAFT GUIDANCE DOCUMENT Comparative Bioavailability Standards: Formulations Used for Systemic Effects 4 This guidance document is being distributed for comment purposes only. 5 6 Published by authority
More informationLessons Learned from the US Prescription Opioid Abuse Epidemic
Lessons Learned from the US Prescription Opioid Abuse Epidemic Michelle Lofwall, M.D. University of KY, Dept. of Psychiatry Center on Drug and Alcohol Research October 3, 2012 Outline for today s talk
More informationClinical Endpoint Bioequivalence Study Review in ANDA Submissions. Ying Fan, Ph.D.
Clinical Endpoint Bioequivalence Study Review in ANDA Submissions Ying Fan, Ph.D. 1 Disclaimer This presentation constitutes an informal communication that represents the best judgment of the speaker at
More informationScientific And Regulatory Background For The Revised Bioequivalence Requirements For NTI, Steep Exposure-Response, And Drugs With Complex PK Profiles
Scientific And Regulatory Background For The Revised Bioequivalence Requirements For NTI, Steep Exposure-Response, And Drugs With Complex PK Profiles Liang Zhao, Ph.D. Director, Division of Quantitative
More informationEgalet Corporate Presentation
Egalet Corporate Presentation Specialty Pharmaceutical Company Focused on Pain 1 NASDAQ: EGLT Forward-Looking Statements Statements included in this presentation that are not historical in nature are "forward-looking
More informationHow to inject op oxycontin
How to inject op oxycontin The Borg System is 100 % How to inject op oxycontin Injecting oxycontin is one of the primary methods of abusing this highly addictive prescription drug. Injecting oxycontin
More informationAbuse-Deterrent Formulations of Opioids: Effectiveness and Value
Abuse-Deterrent Formulations of Opioids: Effectiveness and Value Evidence Report June 28, 2017 Prepared for: Institute for Clinical and Economic Review, 2017 ICER Staff/Consultants Reiner Banken, MD, MSc
More informationBACKGROUND PAPER FOR FDA GUIDANCE DOCUMENT
I. INTRODUCTION BACKGROUND PAPER FOR FDA GUIDANCE DOCUMENT This document provides background and structure for the FDA to support development of a Guidance Document to industry on the development of abuse-deterrent
More informationOpioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Opioid Step Policy Page: 1 of 6 Last Review Date: March 16, 2018 Opioid Step Policy Description
More informationPharmacokinetic and absolute bioavailability studies in early clinical development using microdose and microtracer approaches.
Pharmacokinetic and absolute bioavailability studies in early clinical development using microdose and microtracer approaches. Lloyd Stevens PhD Senior Research Fellow Pharmaceutical Profiles Nottingham,
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationPharmacokinetics of strong opioids. Susan Addie Specialist palliative care pharmacist
Pharmacokinetics of strong opioids Susan Addie Specialist palliative care pharmacist What is the difference between pharmacokinetics and pharmacodynamics? Definitions Pharmacokinetics = what the body does
More informationIOM Workshop on Comparative Oncology Pharmacokinetics in Companion Animal Cancer Studies
IOM Workshop on Comparative Oncology Pharmacokinetics in Companion Animal Cancer Studies Daniel L. Gustafson, Ph.D. Professor Shipley University Chair in Comparative Oncology Director of Basic Research,
More informationCannabis in the Workplace
Cannabis in the Workplace Ryan Vandrey, PhD Johns Hopkins University School of Medicine Disclosures Paid consultant to Zynerba Pharmaceuticals, Battelle Memorial Institute None of my consulting is directly
More informationOxycodone DETERx : A Novel Abuse-Deterrent, Extended-Release Analgesic Option for the Treatment of Patients with Chronic Pain
Pain Ther (2016) 5:171 186 DOI 10.1007/s40122-016-0062-1 REVIEW Oxycodone DETERx : A Novel Abuse-Deterrent, Extended-Release Analgesic Option for the Treatment of Patients with Chronic Pain Jeff Gudin
More informationThe Challenge of Treating Pain
FDA Charge to the Committee: FDA Opioid Action Plan and Incorporating the Broader Public Health Impact into the Formal Risk-Benefit Assessment for Opioids Robert M. Califf, MD Commissioner of Food and
More informationOpiate Use Disorder and Opiate Overdose
Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5
More informationOXYCONTIN Diversion & Abuse Drug Enforcement Administration Office of Diversion Control October 2003
OXYCONTIN Diversion & Abuse Office of Diversion Control October 2003 OXYCONTIN OxyContin is a controlled release form of Schedule II oxycodone Manufactured in tablet form and intended for oral ingestion
More informationPublic Assessment Report Scientific discussion. Naloxone Adapt (naloxone hydrochloride) SE/H/1665/01-02/DC
Public Assessment Report Scientific discussion Naloxone Adapt (naloxone hydrochloride) SE/H/1665/01-02/DC This module reflects the scientific discussion for the approval of Naloxone Adapt. The procedure
More informationPAIN & ANALGESIA. often accompanied by clinical depression. fibromyalgia, chronic fatigue, etc. COX 1, COX 2, and COX 3 (a variant of COX 1)
Pain - subjective experience associated with detection of tissue damage ( nociception ) acute - serves as a warning chronic - nociception gone bad often accompanied by clinical depression fibromyalgia,
More informationTITLE: Tamper-Resistant Oxycodone: A Review of the Clinical Evidence and Costeffectiveness
TITLE: Tamper-Resistant Oxycodone: A Review of the Clinical Evidence and Costeffectiveness DATE: 25 June 2015 CONTEXT AND POLICY ISSUES Oxycodone is a prescription opioid used for chronic and acute pain
More informationDefinitive QTc Assessment in Early Phase Trials: Expectations from FDA s Interdisciplinary Review Team
Definitive QTc Assessment in Early Phase Trials: Expectations from FDA s Interdisciplinary Review Team Jiang Liu, Ph.D. Scientific Lead for QT-IRT Division of Pharmacometrics Office of Clinical Pharmacology
More informationPrescription Opioid Abuse: Abuse-Deterrent Opioids as Part of a Multipronged Approach. For Pfizer Use Only
Prescription Opioid Abuse: Abuse-Deterrent Opioids as Part of a Multipronged Approach Table of Contents Chronic Pain and Prescription Opioids Source of Prescription Opioids and Patient Risk Assessment
More informationKey points. o Potential for nonmedical use, abuse, and diversion of new products
RADARS System Technical Report # 2012Q2-1 Use of unique recipients of dispensed drug (URDD) in assessing the burden of abuse, misuse, and diversion of prescription opioid products Key points Considering
More informationOpioid Pharmacology. Dr Ian Paterson, MA (Pharmacology), MB BS, FRCA, MAcadMEd. Consultant Anaesthetist Sheffield Teaching Hospitals
Opioid Pharmacology Dr Ian Paterson, MA (Pharmacology), MB BS, FRCA, MAcadMEd Consultant Anaesthetist Sheffield Teaching Hospitals Introduction The available opioids and routes of administration - oral
More informationGuidance for Industry
Guidance for Industry Assessment of Abuse Potential of Drugs DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document
More informationDevelopment of Abuse- Resistant Opioid Formulations
Development of Abuse- Resistant Opioid Formulations William K. Schmidt, PhD VP, Clinical Research, Renovis, Inc. Opioid Risk Management, March 29, 2005 Mrs Winslow's Soothing Syrup For children teething.
More informationGOVERNMENT S ROLE IN ADDRESSING PRESCRIPTION DRUG ABUSE
POSITION PAPER GOVERNMENT S ROLE IN ADDRESSING PRESCRIPTION DRUG ABUSE Governments across Canada are concerned about the abuse of prescription drugs, with recent policy discussions focused on mitigating
More informationIPAC-RS/UF Orlando Inhalation Conference March 20, S.T. Horhota 1, C.B. Verkleij 2, P.J.G. Cornelissen 2, L. Bour 3, A. Sharma 3, M.
IPAC-RS/UF Orlando Inhalation Conference March 20, 2014 Case Study: Pharmacokinetics and Pharmacodynamics of Tiotropium and Salmeterol Following Parallel Administration in COPD Patients Using Different
More informationNovel Formulations to Modify Mealtime Insulin Kinetics
Novel Formulations to Modify Mealtime Insulin Kinetics Alan Krasner, Roderike Pohl, Patrick Simms, Philip Pichotta, Robert Hauser, Errol De Souza Biodel, Inc. Danbury, CT Disclosure All authors are employees
More informationDecentralised Procedure. Public Assessment Report
Decentralised Procedure Public Assessment Report Targin 2,5mg/1,25 mg, 15mg/7,5mg, 30mg/15mg Retardtabletten Oxycodone hydrochloride / Naloxone hydrochloride dihydrate DE/H/1612/005-007/DC Applicant: Mundipharma
More informationTITLE: Crushed Buprenorphine or Buprenorphine-Naloxone for Opioid Dependency: A Review of the Clinical Effectiveness and Guidelines
TITLE: Crushed Buprenorphine or Buprenorphine-Naloxone for Opioid Dependency: A Review of the Clinical Effectiveness and Guidelines DATE: 18 July 2016 CONTEXT AND POLICY ISSUES Opioid dependence is a chronic
More informationDMPK. APRIL 27 TH 2017 Jan Neelissen Scientific Adviser Science & Technology
DMPK APRIL 27 TH 2017 Jan Neelissen Scientific Adviser Science & Technology What I learned is a good DMPK profile have acceptable water solubility for development be completely absorbed, preferably via
More informationClinical Studies in BE Evaluation of Generic Products. Brenda S. Gierhart, M.D. Medical Officer, Division of Clinical Review, Office of Generic Drugs
Clinical Studies in BE Evaluation of Generic Products Brenda S. Gierhart, M.D. Medical Officer, Division of Clinical Review, Office of Generic Drugs 1 Disclaimer The opinions and information in this presentation
More informationRule Governing the Prescribing of Opioids for Pain
Rule Governing the Prescribing of Opioids for Pain 1.0 Authority This rule is adopted pursuant to Sections 14(e) and 11(e) of Act 75 (2013) and Sections 2(e) and 2a of Act 173 (2016). 2.0 Purpose This
More informationSection 5.2: Pharmacokinetic properties
Section 5.2: Pharmacokinetic properties SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationAbuse, Misuse, and Diversion of Prescription Opioids: Evaluating the Problem and Proposed Solutions
Abuse, Misuse, and Diversion of Prescription Opioids: Evaluating the Problem and Proposed Solutions Eric Lavonas, MD, FACEP, FACMT, FAACT Associate Director, Rocky Mountain Poison & Drug Center Denver
More informationNonclinical Safety Evaluation of Inhalation Drug Products
Nonclinical Safety Evaluation of Inhalation Drug Products February 13, 2002 Life Science Research Organization Bethesda, Maryland Luqi Pei, Ph.D. Division of Pulmonary and Allergy Drug Products Center
More informationCHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Size and Growth of the Market Issues and trends Leading Competitors CHAPTER TWO: INTRODUCTION AND OVERVIEW Definition of Pain Magnitude
More informationDisclaimer. New Technologies for Abuse Prevention and Treatment. Sanford M. Silverman, MD
New Technologies for Abuse Prevention and Treatment Sanford M. Silverman, MD Disclaimer Speaker: Purdue, Depomed, DSI, BDSI, AZ Institute of Pain Management, Pompano Beach, Florida Medical Director, Compassionate
More informationEvolution of the Opioid Epidemic
Clinical Directors Network, Inc. (CDN) Evolution of the Opioid Epidemic February 5, 2018 2:30 PM-4:00 PM EST Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center, Denver Health Professor,
More informationPrescription Opioid Dependence and Addiction: Experience in the United States
Prescription Opioid Dependence and Addiction: Experience in the United States September 27, 2013 Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center Professor, University of Colorado
More informationInterventions in Prescription Opioid Abuse Do (or can) Prescription Monitoring Programs Make a Difference?
Interventions in Prescription Opioid Abuse Do (or can) Prescription Monitoring Programs Make a Difference? Richard C. Dart, MD, PhD Executive Director of RADARS System, Denver, Colorado Professor, University
More informationValue of Abuse-Deterrent Opioids. For your personal use. Not for further distribution.
Value of Abuse-Deterrent Opioids HHS Data Show that Prescription Opioid Abuse Continues To Be a Serious Public Health Issue At least half of all opioid overdose deaths in the United States (US) involve
More informationSOME STATISTICAL CONSIDERATIONS IN THE DESIGN AND ANALYSIS OF EQUIVALENCE STUDIES USING PHARMACODYNAMIC AND CLINICAL ENDPOINTS
SOME STATISTICAL CONSIDERATIONS IN THE DESIGN AND ANALYSIS OF EQUIVALENCE STUDIES USING PHARMACODYNAMIC AND CLINICAL ENDPOINTS Scott Haughie, M.Sc., Senior Director, Biostatistics IPAC-RS/UF Orlando Inhalation
More informationYear in review. Vit Perlik Director of Regulatory Science and Clinical Development
Year in review Vit Perlik Director of Regulatory Science and Clinical Development Content Year in review Covering September 2013 to September 2014 Where the regulation goes selection of events for illustration
More informationCarnitine and sports medicine: Use or abuse?
Carnitine and sports medicine: Use or abuse? Eric P. Brass, M.D., Ph.D. Professor of Medicine, UCLA School of Medicine Director, Harbor-UCLA Center for Clinical Pharmacology Disclosure: Dr. Brass is a
More informationIncrease in Opioid Related Deaths What the Data Can Tell us. Ontario Methadone Prescriber s Conference November 7, 2014 Tara Gomes
Increase in Opioid Related Deaths What the Data Can Tell us Ontario Methadone Prescriber s Conference November 7, 2014 Tara Gomes Objectives Prescription Opioid Misuse and Abuse: How did we get here? Opioid
More informationRevised European Guideline on PK and Clinical Evaluation of Modified Release Dosage Forms
1st MENA Regulatory Conference on Bioequivalence, Biowaivers, Bioanalysis and Dissolution Jordan September 23 24, 2013 Revised European Guideline on PK and Clinical Evaluation of Modified Release Dosage
More informationStudy Centers: This study was conducted in 2 centers in Italy.
Title of Trial: A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson
More informationPharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco
Pharmacotherapy for opioid addiction Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco Disclosure slide No commercial conflicts to disclose. Gaps in current treatment of opioid
More informationCase Study. Bill a patient with chronic low back pain. 45 years old Divorced, father of two children ages 11 and 16.
Case Study Bill a patient with chronic low back pain Demographics: 45 years old Divorced, father of two children ages 11 and 16. Shares joint custody with his ex-wife and has the children every other weekend
More informationSafety Pharmacology Society Webinar: Simon Authier, DVM, MBA, PhD Director - Safety Pharmacology and Veterinary Science CIToxLAB North America
Safety Pharmacology Society Webinar: Simon Authier, DVM, MBA, PhD Director - Safety Pharmacology and Veterinary Science CIToxLAB North America Agenda Introduction GI presentation rescheduled Upcoming SPS
More informationThe use of Saliva instead of Plasma as a Surrogate in Drug Bioavailability and Bioequivalence Studies in Humans
The use of Saliva instead of Plasma as a Surrogate in Drug Bioavailability and Bioequivalence Studies in Humans ا.د. ناصر محمد ياسر نمرادكيدك Prof. Nasir M. Idkaidek University of Petra Amman - Jordan
More informationMN-221, a Novel Beta2-Adrenergic Agonist for Treatment of Acute Asthma and COPD
MN-221, a Novel Beta2-Adrenergic Agonist for Treatment of Acute Asthma and COPD Brian M. Sadler PhD, Alan Dunton MD, Ernest Kitt, James Bosley PhD, Ron Beaver PhD November 2010 MediciNova, Inc. Rosa &
More informationAbsolute bioavailability and pharmacokinetic studies in early clinical development using microdose and microtracer approaches.
Absolute bioavailability and pharmacokinetic studies in early clinical development using microdose and microtracer approaches. Dr Lloyd Stevens Senior Research Fellow Pharmaceutical Profiles Nottingham,
More informationHTX-011 Postoperative Pain Program Topline Results from Phase 2b Studies. June 21, 2018
HTX-011 Postoperative Pain Program Topline Results from Phase 2b Studies June 21, 2018 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities
More informationThe Opportunity: c-ibs and pain relief with confidence YKP10811
The Opportunity: c-ibs and pain relief with confidence YKP10811 1 TABLE OF CONTENTS Profile Summary Clinical Data Mode of Action Pharmacologic Profile Safety and Toxicity Profile ADME Overview vs. Competitors
More informationNew London CARES Coordinated Access, Resources, Engagement and Support
New London CARES Coordinated Access, Resources, Engagement and Support What are Opioids? Class of drugs that include Heroin Prescription pain relievers oxycodone (OxyContin), hydrocodone (Vicodin), codeine,
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationPreclinical Requirements for Therapeutic Studies in Humans with Advanced Cancer
Preclinical Requirements for Therapeutic Studies in Humans with Advanced Cancer Scott Laurie MD, FRCPC The Ottawa Hospital Cancer Centre Associate Professor, University of Ottawa Disclosures I have no
More informationDrug/Device Combination Products: Bioequivalence
Drug/Device Combination Products: Bioequivalence Three stories:. The story of Nasal and Inhalation Product BE 2. The story of the Generic Auto-Injector 3. The story of User Interface Considerations Bioequivalence
More informationOpioid Use Disorders &Medication Treatment
Agency medical director comments Opioid Use Disorders &Medication Treatment Charissa Fotinos, MD, MSc Deputy Chief Medical Officer Washington State Health Care Authority Learning Objectives: 1) Review
More informationAdaptive and Innovative Study Designs to Accelerate Drug Development from First-In-Human to First-In-Patient
Adaptive and Innovative Study Designs to Accelerate Drug Development from First-In-Human to First-In-Patient Michelle L. Combs, PhD Vice President, Clinical Pharmacology Sciences New Drug And Biologics
More informationFentanyl and Synthetic Opioids- Awareness and the Enforcement Pillar. July-16-18
Fentanyl and Synthetic Opioids- Awareness and the Enforcement Pillar Opioid Situation-How we got here 2012 Oxycontin moves to the tamper proof version OxyNeo (Purdue Pharma) 2012/2013 Patch diversion and
More informationNo! No! No! No! With the possible exception of humans Public Health Question Does the compound have the potential to be abused? Public Health Question Does the compound have the potential to be abused?
More information